RTICC Guest Seminar- Prof. Moshe Elkabets

Assoc. Prof. Moshe Elkabets
The Shraga Segal Department of Microbiology and Immunology, Ben Gurion University of the Negev

“Modulating the Tumor Microenvironment to Restore Immunotherapy Sensitivity”

Abstract: In my talk at RTICC, I will highlight how our lab is tackling one of the most pressing challenges in cancer immunotherapy—resistance to anti-PD1 treatment. I will present our recent findings demonstrating that rational therapy combinations can sensitize tumors to anti-PD1, and that the timing and sequencing of treatments significantly impact therapeutic efficacy. I will also discuss our efforts to improve patient selection through better biomarkers and predictive tools, aiming to identify those most likely to benefit from treatment. Finally, I’ll introduce our novel therapeutic approach—a bispecific antibody designed to overcome anti-PD1 resistance by engaging the immune system in a more targeted and effective manner. Our work bridges fundamental research with clinical relevance, and we hope it will contribute to the development of more personalized and durable cancer immunotherapies.

The RTICC aspires to become a leading center, attracting top-tier researchers renowned both nationally and internationally for their contributions to cancer research in various fields.
A key objective is to foster collaborations and engage with leading scientists, all with the aim of advancing cancer treatment and improving patient outcomes. Therefore, we host the RTICC International Guest Seminar, which is delivered by acclaimed expert academic speakers.